SGLT-2 Inhibitor: Difference between revisions
(→Common) |
|||
| Line 8: | Line 8: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Euglycemic DKA<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref> | *Euglycemic [[DKA]]<ref>[https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood]</ref> | ||
===Common=== | ===Common=== | ||
Revision as of 03:20, 18 April 2017
Administration
- Type: Diabetes medication
- Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- UTI
- Genital candidiasis
- Weight loss
- Dehydration/Orthostasis
Mechanism of Action
- Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule